Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Intrinsic Value
The intrinsic value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock under the Base Case scenario is 10.74 CNY. Compared to the current market price of 11.55 CNY, Shenzhen Hepalink Pharmaceutical Group Co Ltd is Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Balance Sheet Decomposition
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Current Assets | 9.6B |
Cash & Short-Term Investments | 2.6B |
Receivables | 1.5B |
Other Current Assets | 5.5B |
Non-Current Assets | 7.7B |
Long-Term Investments | 1.8B |
PP&E | 2.6B |
Intangibles | 2.8B |
Other Non-Current Assets | 488.5m |
Free Cash Flow Analysis
Shenzhen Hepalink Pharmaceutical Group Co Ltd
CNY | |
Free Cash Flow | CNY |
Earnings Waterfall
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Revenue
|
5.3B
CNY
|
Cost of Revenue
|
-3.5B
CNY
|
Gross Profit
|
1.7B
CNY
|
Operating Expenses
|
-1.1B
CNY
|
Operating Income
|
649m
CNY
|
Other Expenses
|
-2.2m
CNY
|
Net Income
|
646.7m
CNY
|
Profitability Score
Profitability Due Diligence
Shenzhen Hepalink Pharmaceutical Group Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shenzhen Hepalink Pharmaceutical Group Co Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd
According to Wall Street analysts, the average 1-year price target for Shenzhen Hepalink Pharmaceutical Group Co Ltd is 7.55 CNY with a low forecast of 7.47 CNY and a high forecast of 7.77 CNY.
Dividends
Current shareholder yield for Shenzhen Hepalink Pharmaceutical Group Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one Shenzhen Hepalink Pharmaceutical Group Co Ltd stock under the Base Case scenario is 10.74 CNY.
Compared to the current market price of 11.55 CNY, Shenzhen Hepalink Pharmaceutical Group Co Ltd is Overvalued by 7%.